Less than five months after receiving a 20 million euro loan from the European Investment Bank (EIB), Univercells announces a new major operation: Walloon biotech is creating a subsidiary with the American capital investment fund KKR to the industrialization of its revolutionary platform intended for the production of vaccines and products for gene and cell therapies.